Severe Hypertriglyceridemia (sHTG)

In this Consultant360 interview, Brian Bergmark, MD explains how olezarsen, an RNA-targeted therapy targeting APOC3, may help address residual cardiovascular risk in patients with moderate...

Novel therapies are reshaping how clinicians think about triglyceride management and residual cardiovascular risk. This quick quiz tests your knowledge of the emerging data on APOC3 inhibition and its...

In this Q&A, Anum Saeed, MD discusses how cardiologists must think beyond LDL and blood pressure, leveraging GLP-1 receptor agonists, SGLT-2 inhibitors, and emerging therapies to reduce cardiovascular...